Entry |
|
Name |
Evobrutinib (USAN/INN) |
Formula |
C25H27N5O2
|
Exact mass |
429.2165
|
Mol weight |
429.51
|
Structure |

|
Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG02022 BTK inhibitor
|
Efficacy |
Anti-inflammatory disease, Bruton's tyrosine kinase inhibitor |
Comment |
Treatment of multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis
|
Target |
|
Pathway |
hsa04662 | B cell receptor signaling pathway |
|
Interaction |
|
Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG02022 BTK inhibitor
D12467 Evobrutinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
TEC family
BTK
D12467 Evobrutinib (USAN/INN)
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 32
1 C8x C 5.6000 -14.8400
2 N5x N 5.6000 -16.2400
3 C8y C 6.8124 -16.9400
4 C8y C 8.0249 -16.2400
5 C8y C 8.0249 -14.8400
6 N5x N 6.8124 -14.1400
7 N1b N 9.2560 -14.1290
8 C1b C 10.4612 -14.8247
9 C1y C 11.6435 -14.1419
10 C1x C 12.8375 -14.8312
11 C1x C 14.0499 -14.1312
12 N1y N 14.0499 -12.7312
13 C1x C 12.8560 -12.0419
14 C1x C 11.6435 -12.7419
15 C5a C 15.2734 -12.0246
16 C2b C 16.4824 -12.7225
17 C2a C 17.6629 -12.0408
18 O5a O 15.2732 -10.6401
19 C8y C 9.2560 -16.9510
20 C8x C 9.2557 -18.3399
21 C8x C 10.4680 -19.0402
22 C8y C 11.6806 -18.3405
23 C8x C 11.6809 -16.9516
24 C8x C 10.4686 -16.2513
25 O2a O 12.8997 -19.0447
26 C8y C 14.0994 -18.3523
27 C8x C 15.2843 -19.0367
28 C8x C 16.4969 -18.3370
29 C8x C 16.4972 -16.9370
30 C8x C 15.3123 -16.2525
31 C8x C 14.0997 -16.9523
32 N1a N 6.8124 -18.3398
BOND 35
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 9 14 1
16 12 15 1
17 15 16 1
18 16 17 2
19 15 18 2
20 4 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 22 23 1
25 23 24 2
26 19 24 1
27 22 25 1
28 25 26 1
29 26 27 2
30 27 28 1
31 28 29 2
32 29 30 1
33 30 31 2
34 26 31 1
35 3 32 1
|